VIRGINIA COMMONWEALTH UNIVERSITY

Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County.

Researchers at University of Virginia and University of Michigan developed a humanized monoclonal antibody targeting citrullinated histone H3 to combat sepsis, which kills approximately 11 million people worldwide annually.

A pilot study of 10 POTS patients found that ivabradine significantly reduced heart rate increases from 40 beats per minute to 15 beats per minute when standing.

Researchers at Virginia Commonwealth University's Massey Comprehensive Cancer Center have developed a novel "Fusion Superkine" (FSK) therapy that combines IL-24S and IL-15 cytokines to both kill glioblastoma tumor cells and activate immune responses.

INmune Bio's XPro™ (XPro1595, pegipanermin) significantly reduced amyloid formation and improved brain function in transgenic mice following traumatic brain injury.

Researchers report successful treatment of ciltacabtagene autoleucel-induced parkinsonism in multiple myeloma patients using the JAK inhibitor ruxolitinib, offering a potential solution for this serious complication.

A landmark Phase 3 clinical trial led by VCU and King's College London researchers found semaglutide significantly reduces liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Aramchol, Galmed Pharmaceuticals' SCD1 inhibitor, significantly enhanced the anti-tumor effects of Bayer's Regorafenib in liver and colorectal cancer models through increased autophagy and death receptor signaling.

A Phase 2 clinical trial of survodutide, a dual GLP-1 and glucagon agonist, demonstrated that up to 83% of patients with fatty liver disease showed measurable improvement after 48 weeks of treatment.